Cel-Sci Corp. (CVM)
XASE:CVM
Want to see CVM full AI Analyst Report?
Top Page
Cel-Sci
(NYSE MKT:CVM)
Select Model
Select Model
Rating:42Neutral
Price Target:
$3.00
▼(-42.20% Downside)
Action:ReiteratedDate:04/30/26
The score is driven primarily by weak financial performance (pre-revenue, ongoing losses and cash burn, plus highly elevated risk from volatile/outlier balance sheet and cash flow figures). Technicals also weigh on the score with a clear downtrend and negative momentum, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Contract manufacturing capability
CEL‑SCI’s GMP contract development and manufacturing capability provides durable fee‑based revenue potential beyond equity raises. Specialized cell and gene bioprocessing can secure multi‑period client contracts, monetize existing assets, and build industry partnerships that help stabilize cash flow over time.
Negative Factors
Pre-revenue, persistent cash burn
CEL‑SCI remains a pre‑revenue, clinical‑stage biotech with sustained negative operating results and ongoing cash burn. Without product sales, the company depends on external financing and contract services; this structural funding need increases dilution risk and makes long‑term planning contingent on successful trials or steady service contracts.
Read all positive and negative factors
Positive Factors
Negative Factors
Contract manufacturing capability
CEL‑SCI’s GMP contract development and manufacturing capability provides durable fee‑based revenue potential beyond equity raises. Specialized cell and gene bioprocessing can secure multi‑period client contracts, monetize existing assets, and build industry partnerships that help stabilize cash flow over time.
Read all positive factors
Cel-Sci (CVM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.61M
Dividend YieldN/A
Average Volume (3M)125.69K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue GrowthN/A
EPS Growth63.57%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.68
Shares Outstanding8,457,967
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.32
Enterprise Value/Ebitda-1.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Cel-Sci Business Overview & Revenue Model
Company Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatm...
How the Company Makes Money
CEL-SCI’s revenue model is primarily based on (1) raising capital to fund research and development and (2) generating service revenue from manufacturing activities. 1) Financing to fund operations: As a clinical-stage biotech, CEL-SCI has historic...
Cel-Sci Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.85M | -3.89M | -3.97M | -3.96M | -3.88M | -499.00K |
| EBITDA | -19.37M | -20.88M | -22.21M | -27.56M | -31.74M | -34.71M |
| Net Income | -23.81M | -25.41M | -26.92M | ― | -38.27M | -39.19M |
Balance Sheet | ||||||
| Total Assets | 22.89M | 28.16M | 26.99M | 30.53M | 50.52M | 75.87M |
| Cash, Cash Equivalents and Short-Term Investments | 6.28M | 10.95M | 4.74M | 4.15M | 22.67M | 42.21M |
| Total Debt | 10.63M | 9.38M | 11.62M | 13.57M | 15.30M | 15.97M |
| Total Liabilities | 11.76M | 12.20M | 14.12M | 17.31M | 18.36M | 19.34M |
| Stockholders Equity | 11.14M | 15.96M | 12.87M | 13.21M | 32.16M | 56.53M |
Cash Flow | ||||||
| Free Cash Flow | -17.01M | -17.16B | -18.91M | -23.22M | -18.90M | -27.83M |
| Operating Cash Flow | -17.00M | -17.12B | -18.81M | -22.85M | -18.24M | -18.79M |
| Investing Cash Flow | -5.16K | -38.11M | -108.09K | -372.26K | 5.49M | -15.18M |
| Financing Cash Flow | 18.67M | 23.37B | 19.51M | 4.69M | -638.43K | 54.52M |
Cel-Sci Technical Analysis
Positive
5.19
Price Trends
4.11
Positive
4.96
Negative
6.52
Negative
Market Momentum
0.18
Negative
67.77
Neutral
89.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVM, the sentiment is Positive. The current price of 5.19 is above the 20-day moving average (MA) of 3.87, above the 50-day MA of 4.11, and below the 200-day MA of 6.52, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 67.77 is Neutral, neither overbought nor oversold. The STOCH value of 89.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVM.
Cel-Sci Risk Analysis
Cel-Sci disclosed 39 risk factors in its most recent earnings report. Cel-Sci reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cel-Sci Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $74.92M | -0.79 | -69.56% | ― | ― | 29.91% | |
48 Neutral | $77.51M | -2.07 | -30.19% | ― | ― | 63.31% | |
48 Neutral | $180.70M | -15.62 | -111.37% | ― | ― | 80.61% | |
42 Neutral | $24.61M | -1.93 | -226.10% | ― | ― | 63.57% |
* Healthcare Sector Average
CVM
Cel-Sci
2.91
-5.07
-63.53%
ATHE
Alterity Therapeutics
4.56
1.11
32.17%
XBIT
XBiotech
2.52
-0.41
-13.99%
PLRX
Pliant Therapeutics
1.21
-0.41
-25.31%
UNCY
Unicycive Therapeutics
7.16
0.66
10.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.